Gynecologic Cancer
The information below is intended for use by health care providers only. Please consult with your health care provider for more information about clinical trials.
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43)
The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer.
Study Details
- Study Site/Tumor Location: Gynecologic Cancer
- Study Location: Miami Valley Hospital South Campus
- Ages eligible for study: 18 years and older
- Genders eligible for study: Female
- Principal Investigator: Dr. Michael Guy
- Other Physicians who can consent: Dr. Guy, Dr. Reid, Dr. Ore
Study Contact Information
- Darinda Reis
- (937) 438-7882 (937) 438-7882
NRG-CC004 Double Blind Dose Finding Trial of Bupropion Vs Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
Study Details
- Study Site/Tumor Location: Breast Cancer (Post-Menopausal)
- Study Location: All Premier
- Ages eligible for study: 18 years and older
- Genders eligible for study: Female
- Principal Investigator: Dr. Gross
- Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz
Study Contact Information
- Sandy Fletcher
- (513) 974-5674 (513) 974-5674
- Sandy Evers
- (937) 734-5972 (937) 734-5972
- Lisa Willey
- (937) 438-7819 (937) 438-7819
- Karen Medders
- (937) 734-5847 (937) 734-5847
- Heather Penwell
- (937) 440-4822 (937) 440-4822
- Darinda Reis
- (937) 438-7882 (937) 438-7882
NRG-GY005 Cediranib + Olaparib combined vs Cediranib or Olaparib alone, or standard of care chemo, recurrent platinum resistant or refractory ovarian, fallopian or primary peritoneal ca.
Study Details
- Study Site/Tumor Location: Gynecology
- Study Location: Miami Valley Hospital South Campus
- Ages eligible for study: 18 years and older
- Genders eligible for study: Female
- Principal Investigator: Dr. Gross
- Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz
Study Contact Information
- Sandy Fletcher
- (513) 974-5674 (513) 974-5674
- Sandy Evers
- (937) 734-5972 (937) 734-5972
- Lisa Willey
- (937) 438-7819 (937) 438-7819
- Karen Medders
- (937) 734-5847 (937) 734-5847
- Heather Penwell
- (937) 440-4822 (937) 440-4822
- Darinda Reis
- (937) 438-7882 (937) 438-7882
NRG-GY006 RT and Cisplatin +/- intravenous Triapine, new diagn. bulky stage IB2, stage II, IIB or IVA ca. uterine cervix or stage II-IVA vag.l ca.
Study Details
- Study Site/Tumor Location: Gynecology
- Study Location: Miami Valley Hospital South Campus
- Ages eligible for study: 18 years and older
- Genders eligible for study: Female
- Principal Investigator: Dr. Gross
- Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz
Study Contact Information
- Sandy Fletcher
- (513) 974-5674 (513) 974-5674
- Lisa Willey
- (937) 438-7819 (937) 438-7819
- Sandy Evers
- (937) 734-5972 (937) 734-5972
- Karen Medders
- (937) 734-5847 (937) 734-5847
- Heather Penwell
- (937) 440-4822 (937) 440-4822
- Darinda Reis
- (937) 438-7882 (937) 438-7882
NRG-GY007 Ruxolitinib with Front-Line Neoadj. and Post-Surgical TX in Adv. Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Study Details
- Study Site/Tumor Location: Gynecology
- Study Location: Miami Valley Hospital South Campus
- Ages eligible for study: 18 years and older
- Genders eligible for study: Female
- Principal Investigator: Dr. Gross
- Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz
Study Contact Information
- Sandy Fletcher
- (513) 974-5674 (513) 974-5674
- Sandy Evers
- (937) 734-5972 (937) 734-5972
- Lisa Willey
- (937) 438-7819 (937) 438-7819
- Karen Medders
- (937) 734-5847 (937) 734-5847
- Heather Penwell
- (937) 440-4822 (937) 440-4822
- Darinda Reis
- (937) 438-7882 (937) 438-7882
NRG-GY014 Tazemetostat in Recurrent or Persistent Endometrioid or Clear Cell Ca of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Study Details
- Study Site/Tumor Location: Gynecology
- Study Location: Miami Valley Hospital South Campus
- Ages eligible for study: 18 years and older
- Genders eligible for study: Female
- Principal Investigator: Dr. Gross
- Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz
Study Contact Information
- Sandy Fletcher
- (513) 974-5674 (513) 974-5674
- Sandy Evers
- (937) 734-5972 (937) 734-5972
- Lisa Willey
- (937) 438-7819 (937) 438-7819
- Karen Medders
- (937) 734-5847 (937) 734-5847
- Heather Penwell
- (937) 440-4822 (937) 440-4822
- Darinda Reis
- (937) 438-7882 (937) 438-7882